Thyroid cancer following childhood low dose radiation exposure:
Lubin, Jay H; Adams, M Jacob; Shore, Roy; Holmberg, Erik; Schneider, Arthur B; Hawkins, Michael M; Robison, Leslie L; Inskip, Peter D; Lundell, Marie; Johansson, Robert; Kleinerman, Ruth A; de Vathaire, Florent; Damber, Lena; Sadetzki, Siegal; Tucker, Margaret; Sakata, Ritsu; Veiga, Lene H S
DOI: 10.1210/jc.2016-3529
Thyroid cancer following childhood low dose radiation exposure: a pooled analysis of nine cohorts


The Journal of Clinical Endocrinology & Metabolism
Endocrine Society

Submitted: October 25, 2016
Accepted: March 02, 2017
First Online: March 08, 2017

Advance Articles are PDF versions of manuscripts that have been peer reviewed and accepted but not yet copyedited. The manuscripts are published online as soon as possible after acceptance and before the copyedited, typeset articles are published. They are posted "as is" (i.e., as submitted by the authors at the modification stage), and do not reflect editorial changes. No corrections/changes to the PDF manuscripts are accepted. Accordingly, there likely will be differences between the Advance Article manuscripts and the final, typeset articles. The manuscripts remain listed on the Advance Article page until the final, typeset articles are posted. At that point, the manuscripts are removed from the Advance Article page.

DISCLAIMER: These manuscripts are provided "as is" without warranty of any kind, either express or particular purpose, or non-infringement. Changes will be made to these manuscripts before publication. Review and/or use or reliance on these materials is at the discretion and risk of the reader/user. In no event shall the Endocrine Society be liable for damages of any kind arising references to, products or publications do not imply endorsement of that product or publication.
Thyroid cancer at low radiation doses

**Thyroid cancer following childhood low dose radiation exposure: a pooled analysis of nine cohorts**

Jay H. Lubin 1, M. Jacob Adams 2, Roy Shore 3,13, Erik Holmberg 4, Arthur B. Schneider 5, Michael M. Hawkins 6, Leslie L. Robison 7, Peter D. Inskip 1,13, Marie Lundell 8, Robert Johansson 9, Ruth A. Kleienerman 1, Florent de Vathaire 10, Lena Damber 9, Siegal Sadetzki 11, Margaret Tucker 1, Ritsu Sakata 3, Lene H. S. Veiga 12

1 Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA;
2 University of Rochester School of Medicine and Dentistry, Department of Public Health Sciences, Rochester, NY, USA
3 Radiation Effects Research Foundation, Hiroshima, Japan
4 Department of Oncology and Radiation Physics and the Oncological Centre, Sahlgrenska University Hospital, Goteborg, Sweden
5 University of Illinois College of Medicine, Section of Endocrinology, Diabetes and Metabolism, Chicago, IL, USA
6 Centre for Childhood Cancer Survivor Studies, Department of Public Health and Epidemiology, University of Birmingham, Birmingham, United Kingdom
7 Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA
8 Department of Medical Physics, Radiumhemmet, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden
9 Oncology, Department of Radiation Sciences, Umeå University, Umeå, Sweden
10 Cancer Epidemiology Research Unit, National Institute for Health and Medical Research- Institut Gustave Roussy, Villejuif, France
11 Cancer and Radiation Epidemiology Unit, The Gertner Institute, Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
12 Institute for Radiation Protection and Dosimetry, Brazilian Nuclear Energy Commission, Rio de Janeiro, Brazil

Received 25 October 2016. Accepted 02 March 2017.

13 Retired

**Context:** The increased use of diagnostic and therapeutic procedures that involve radiation raises concerns about radiation effects, particularly in children and to the radio-sensitive thyroid gland.

**Objectives:** Evaluation of relative risk (RR) trends for thyroid radiation doses <0.2 gray; evidence of a threshold dose; and possible modifiers of the dose-response, e.g., sex, age at exposure, time since exposure.

**Design and setting:** Pooled data from nine cohort studies of childhood external radiation exposure and thyroid cancer with individualized dose estimates, ≥1,000 irradiated subjects or ≥10 thyroid cancer cases, with data limited to individuals receiving doses <0.2 gray.

**Participants:** Cohorts included: childhood cancer survivors (n=2); children treated for benign diseases (n=6); and children who survived the atomic bombings in Japan (n=1). There were 252 cases and 2,588,559 person-years in irradiated individuals and 142 cases and 1,865,957 person-years in non-irradiated individuals.

**Intervention:** There were no interventions.

**Main Outcome Measure:** Incident thyroid cancers.
**Results:** For both <0.2 gray and <0.1 gray, RRs increased with thyroid dose (P<0.01), without significant departure from linearity (P=0.77 and P=0.66, respectively). Estimates of threshold dose ranged from 0.0 to 0.03 gray, with an upper 95% confidence bound of 0.04 gray. The increasing dose-response trend persisted >45 years after exposure, was greater at younger age at exposure and younger attained age and was similar by sex and number of treatments.

**Conclusions:** Our analyses reaffirmed linearity of the dose-response as the most plausible relationship for ALARA (“as low as reasonably achievable”) assessments for pediatric low dose radiation-associated thyroid cancer risk.

A pooled analysis of 9 cohorts confirms linearity of childhood thyroid radiation dose and thyroid cancer at low radiation doses (<0.2 Gy). Risks arise within 5-10 years and persist for 45+ years. A pooling of nine cohort studies of childhood external radiation exposure revealed a linear increase in risk of thyroid cancer and reaffirmed the “as low as reasonably achievable” principal for pediatric low dose radiation.

The increasing use of diagnostic and therapeutic medical procedures that involve radiation raises concerns about the consequences of low dose irradiation on cancer occurrence and in particular whether linear-based extrapolations represent the best estimate of low dose cancer risk or whether a threshold dose, below which there is no risk of radiation-induced cancer, might exist (1-3) (see [http://dels.nas.edu/Upcoming-Event/Planning-Towards-BEIR-VIII-Report/AUTO-0-14-84-B](http://dels.nas.edu/Upcoming-Event/Planning-Towards-BEIR-VIII-Report/AUTO-0-14-84-B)). With increased radiation exposures of children and the well-documented radio-sensitivity of the thyroid gland, data on thyroid cancer incidence among low dose thyroid irradiated children provide an opportunity to address issues of pediatric radiation-associated thyroid cancer risk in relation to assessments of ALARA (“as low as reasonably achievable”), with implications for both clinical practice and radio-epidemiology (3-7). With these considerations in mind, we pool epidemiologic studies on children exposed to external radiation and analyze thyroid cancer incidence for those exposed at low doses.

A recent pooling of 12 epidemiologic studies of thyroid cancer following radiation exposure in childhood included a broad range of thyroid radiation doses, from <0.1 gray (Gy) for treatment of benign diseases and exposures following the atomic bombings in Japan to >60 Gy resulting from radiation therapies for various childhood cancers (8). Analyses revealed a curvilinear relationship, with relative risks (RR) increasing supra-linearly through about 2-4 Gy, leveling at doses between 10-30 Gy with RRs of 30 to 40 and declining thereafter, with RRs remaining 5 to 10 at 50-60 Gy. The leveling and downturn at higher doses may have reflected cell killing effects, although compensatory accelerated stem cell repopulation may have partially mitigated the decline (9). The pooled analysis reported increased RRs for doses <0.1 Gy, but did not fully explore the result (8). Investigators also identified important modifiers of the dose-response association, namely, radiation dose response trends emerged within 5-10 years of exposure, increased at younger ages at exposure, declined with increasing attained age and persisted for 50 years and more after exposure (8, 10). Trends were comparable in strength for females and males. Notably, these analyses did not address whether patterns of effect modification derived exclusively from those exposed at moderate and high doses or whether there were similar patterns among those exposed only at lower doses.

Questions about thyroid cancer risks at low thyroid radiation doses in children are best addressed using data in children exposed at low doses. We therefore examined data in children exposed at low doses to consider: (i) RR patterns at doses <0.2 Gy and <0.1 Gy; (ii) the possible existence of a threshold dose; and (iii) modification of the dose-response by sex, age at exposure, attained age, years since exposure and radiation dose fractionation.
METHODS

Study populations

We used MEDLINE to identify 12 epidemiologic (10 cohort and two case-control) studies of childhood external radiation exposure and thyroid cancer and approached the principal investigators to collaborate in a pooled data analysis. We required that studies had sufficient information for the calculation of individualized, quantitative, thyroid gland-specific dose estimates and enrolled at least 1,000 irradiated subjects or 10 thyroid cancers (8). Given the highly specialized characteristics of the studies and, for cohorts, the need to accommodate continued follow-up, we were confident that these studies represented all eligible studies. After the pooling of data and harmonization of variables, the current analysis restricted data to doses <0.2 Gy, except where noted. This resulted in the exclusion of two case-control studies following treatment for childhood cancer (11, 12) and one cohort study of childhood lymphoid hyperplasia (13). Since there were no thyroid cancer cases <0.2 Gy, except for one non-exposed case for one study (11), and since analyses adjusted for study, the three omitted studies provided no information for the evaluation of RR patterns. Nine cohorts remained, including treatment for childhood cancer (n=2), treatment for various benign diseases (e.g., tinea capitis, enlarged thymus, hemangioma and enlarged tonsils and adenoids) (n=6), and Japanese atomic bomb survivors (n=1) (Appendix Table 1). Detailed study-specific descriptions and study-specific analyses are found in reference (8) and its Supplemental Material. Cases were those who developed incident thyroid cancer during follow-up. Excluding non-melanoma skin cancer, cases represented first primary cancers for studies of benign diseases and atomic bomb survivors and second primary cancers for studies of childhood cancer survivors. We censored autopsy-identified thyroid cancers at death, but did not include them as cases.

The institutional review boards approved each participating study and the data pooling.

Models for thyroid cancer risk

For seven cohorts, follow-up started at date of first radiation exposure or enrollment for non-exposed (Appendix Table 1). For the Atomic Bomb Survivors study, follow-up started in 1958, 13 years after exposure. For the Childhood Cancer Survivor Study (CCSS) cohorts, follow-up started five (CCSS-US) or three years (CCSS-Fr/UK) after first cancer. Follow-up continued to the earliest date of death, loss to follow-up, incident cancer other than non-melanoma skin cancer or end of study. Analyses used Poisson regression, with person-years of follow-up cross-tabulated by study, sex, age at exposure, calendar year of follow-up, time since exposure, attained age, treatment with chemotherapy, thyroid radiation dose and number of radiation treatments, where one treatment encompassed all doses within six months. Regressions adjusted for study, sex and age and selected study-specific variables. For the Israel Tinea Capitis study, variables included country of origin (North Africa/Others) and comparison group (sibling/population). For the Rochester Thymus study, variables included the presence of goiter (yes/no) and Jewish religion (yes/no). For the Atomic Bomb Survivors study, variables included city of exposure (Hiroshima/Nagasaki), not in city at the bombing (yes/no) and enrollment in the Adult Health Study (yes/no), the latter variable accounting for possible surveillance-related differences in thyroid cancer rates (10). For CCSS cohorts, additional variables included type of first cancer (Hodgkin lymphoma or other) and chemotherapy treatment. Since most radiation-exposed cases had only one treatment (84%), we assumed one treatment for exposed patients who were missing number of treatments. We computed person-years weighted means within each cell of the cross-tabulation for continuous variables.
The Appendix provides methodologic details. The regression model for thyroid cancer incidence rate, \( r(x,d,c) \), included adjustment variables \( x \), thyroid radiation dose \( d \) and chemotherapy exposure \( c \). We previously determined that an additive relationship best described the joint association of radiation exposure and chemotherapy treatment (\( c = 1 \) if yes and \( c = 0 \) if no). Given \( x \), the incidence rate under an additive relationship for radiation dose and chemotherapy, termed non-synergistic, is the sum of three terms: the incidence rate absent both factors, \( r(x,0,0) \), and the excess rates for each exposure at the referent level of the other, \( \{r(x,d,0)-r(x,0,0)\} \) and \( \{r(x,0,c)-r(x,0,0)\} \) (14, 15), i.e.,

\[
\begin{align*}
\text{r}(x,d,c) &= \text{r}(x,0,0) + \{\text{r}(x,d,0) - \text{r}(x,0,0)\} + \{\text{r}(x,0,c) - \text{r}(x,0,0)\}
\end{align*}
\]

Factoring the non-exposed thyroid cancer rate, \( \text{r}(x,0,0) \), \( r(x,0,0) = \text{r}_0(x) \{1 + \text{ERR}(d) + \theta c\} \) (1)

where \( \text{ERR}(d) \) was the radiation-associated excess relative risk (ERR) and \( \theta \) was the chemotherapy-associated ERR. We set \( \text{r}_0(x) = \exp(\phi x) \) with \( \phi \) a vector of parameters. For <0.2 Gy, we fitted a simple linear model, \( \text{ERR}(d) = \beta d \), where \( \beta \) was the ERR/Gy, i.e., the slope. We examined departures from linearity with likelihood ratio tests and used a likelihood-based 95% confidence interval (CI) for estimates of \( \beta \).

A threshold identifies a dose below which there is no radiation effect, while a linear threshold model specifies a linear relationship starting at the threshold dose, i.e., \( \text{ERR}(d) = \beta (d - \eta)_+ \), where \( (d - \eta)_+ = \max(0,d - \eta) \) with \( \eta \) the unknown threshold. We compared deviances to identify the maximum likelihood estimate for the threshold. We also modeled the dose-response using a 4-knot cubic spline (16, 17). Finally, we compared the full dose range model (8), but fitted to the nine cohorts in this analysis.

We used the Epicure program for all modeling (18).

RESULTS

For doses <0.2 Gy and <0.1 Gy, there were 252 and 184 radiation-exposed thyroid cancer cases, respectively, and 2,588,559 and 2,114,683 person-years of follow-up (Appendix Table 1). Among non-exposed individuals, there were 142 thyroid cancer cases and 1,865,957 person-years.

Radiation dose-response

For doses <0.2 Gy, RRs increased significantly with radiation dose (Table 1 and Figure 1, main panel, solid black line) (\( P < 0.01 \)), with no significant departure from linearity (\( P = 0.77 \)). A moving-average smoothing of RRs (thick grey line) with plus and minus one standard deviation (thin grey line) highlighted the linear pattern. The downward extrapolation from the curvilinear model fitted to the full dose range closely approximated low dose RRs (dash line). Results were similar for <0.1 Gy (inset panel), with no departure from linearity (\( P = 0.66 \)).

For <0.2 Gy and <0.1 Gy, estimates of \( \beta \) were 11.1 (95% CI, 6.6, 19.7) and 9.6 (95% CI, 3.7, 17.0), respectively, with fitted RRs at 0.2 Gy of 3.2 (95% CI, 2.3, 4.3) and 2.9 (95% CI, 1.7, 4.5). Using the full dose range model, the fitted RR at 0.2 Gy was 2.7 (95% CI, 2.1, 3.4).

The cubic spline was flat through 0.03 Gy (Figure 1, dot line), largely influenced by the RR of 0.9 (95% CI, 0.5, 1.6) for the 0.02-0.03 Gy dose category with 13 cases (Table 1).
Nonetheless, the simple linear model had the minimum Akaike Information Criterion (19), identifying it as the preferred model.

**Estimates of a threshold dose**

We examined deviances to estimate threshold dose ($\eta$). For $<0.2$ Gy, deviances (open circle) and a moving-average smoothing (solid line) increased (i.e., poorer fit) with possible threshold values, with minimum deviance (star symbol) at 0.00 Gy (Figure 2, main panel). Deviances changed little through 0.02 Gy. For $<0.1$ Gy, the minimum deviance occurred at 0.025 Gy, with no change through 0.03 Gy (inset panel), indicating limited ability to identify a specific threshold. One-sided upper 95% CIs were 0.036 Gy for $<0.2$ Gy and 0.044 for $<0.01$ Gy (dash line).

**Excess radiation-associated thyroid cancers**

Using the equation for doses $<0.2$ Gy, we estimated 37.2% radiation-associated thyroid cases (252 observed with 93.8 excess exposed cases) (Table 1). This varied from 5.7% (54 observed with 3.1 excess cases) for doses $<0.02$ Gy to 54.4% (68 observed with 37.0 excess cases) for doses between 0.1 and 0.2 Gy.

**Modification of the radiation dose-response**

The radiation dose-response was similar by sex ($P=0.35$) and number of treatments ($P=0.25$) (Table 2). The dose-response generally increased with younger age at exposure, except for those exposed under age one year ($P=0.01$). Radiation dose-responses decreased with greater attained age ($P=0.01$) and decreased but remained elevated with years since exposure ($P=0.02$), persisting 45 years and more after irradiation. Appendix Figure 1 displays fitted RRs at 0.2 Gy and models using continuous modifiers, illustrating the wide confidence interval for the RR under age one year. These effect modification patterns were similar for doses $<0.1$ Gy (Table 2), though estimates were less stable. Results paralleled those in the complete data (8).

**Consistency of radiation effects across cohorts**

We evaluated the influence of each study, with particular attention to the Tinea Capitis study and the Atomic Bomb Survivors study, since they contributed 52% (132/252) and 28% (70/252) of exposed cases, respectively. For $<0.2$ Gy and with an adjustment to reflect age five years at exposure to account for cohort differences, the fitted RR at 0.2 Gy was 3.2 (95% CI, 2.4, 4.5) for all studies combined (Figure 3, upper panel). With the Tinea Capitis study omitted, the fitted RR estimate at 0.2 Gy decreased 31% to 2.2 (95% CI, 1.5, 4.0) and with the Atomic Bomb Survivors study omitted, the estimate increased 25% to 4.0 (95% CI, 2.8, 6.1). Omitting other studies individually, as well as both CCSS cohorts, did not alter the summary estimate. For $<0.1$ Gy, the Tinea Capitis and Atomic Bomb Survivors studies contributed 82% (150/282) of exposed cases and omission of each study resulted in similar consequences.

We assumed the same ERR/Gy applied in all study populations. Allowing random effects for ERR/Gy ($\beta$) due to population differences and adjusting for age at exposure, Cochran’s Q-statistics were $P=0.89$ for doses $<0.2$ Gy and $P=0.95$ for doses $<0.1$ Gy indicating homogeneity of the ERR/Gy across studies (20-22). The random effects fitted RRs at 0.2 Gy were 3.0 (95% CI, 2.1, 4.9) for $<0.2$ Gy and 2.9 (95% CI, 1.7, 6.6) for $<0.1$ Gy.

**Discussion**

Given enhanced effects for childhood radiation exposures and the well-documented radio-sensitivity of the thyroid gland, our pooling of all epidemiologic data with thyroid radiation doses $<0.2$ Gy enabled a direct assessment of a linear dose-response relationship for thyroid
cancer risk and of a possible threshold dose. The analysis included 252 radiation exposed thyroid cancer cases and was the most definitive to date of thyroid cancer following low dose external radiation exposure.

For <0.2 Gy and <0.1 Gy, RRs increased significantly with thyroid radiation dose, with trends consistent with linearity. Fitted estimates of RRs at these doses were also consistent with downward extrapolations with previous models based on all doses through 70+ Gy. Consequently, our results refute suggestions of no excess radiation-related thyroid cancer risk below these a priori restriction levels and support linearity in ALARA assessments.

Estimates of a threshold dose were 0.0 Gy for <0.2 Gy and 0.03 Gy for <0.1 Gy. These estimates derived from the likelihood profile and therefore represented maximum likelihood estimates (23). One-sided upper 95% confidence limits were 0.036 Gy and 0.044 Gy, respectively. Analysis did not account for dose measurement error, which may have introduced bias, typically an underestimation (24, 25). However, for the Atomic Bomb Survivors study, we used measurement error-adjusted dose estimates (26, 27). For the Tinea Capitis study, an analysis that accounted for measurement error estimated a similar dose response and assessment of effect modifiers (28, 29). With the Tinea Capitis and the Atomic Bomb Survivors studies comprising 80% of exposed cases and 57% of exposed person-years, it was thus unlikely that measurement error substantially affected estimates of threshold dose, although a definitive conclusion was not possible.

A comprehensive accounting of dose measurement error for all studies was beyond the scope of this paper. In particular, we did not know to what extent dosimetric conditions of the Tinea Capitis study applied to other studies. Nevertheless, we note one potential contribution to dose measurement error for some CCSS participants, namely, an underestimation of thyroid dose from additional radiological examinations associated with cancer diagnosis, treatment monitoring and follow-up. This additional dose, more likely with head and neck cancers, was not captured in the dose assessments and may have amounted to 0.2 Gy and more. Since CCSS cohorts included 5% of cases and 3% of person-years and since influence analysis indicated minimal impact from the omission of CCSS studies, any underestimation of radiation doses in CCSS data likely involved minimal bias.

The 12-study pooled analysis supported a minimum latency of 5-10 years (8). For 5-9, 10-14 and 15-19 years since exposure, there were 39, 65 and 128 exposed thyroid cancers, respectively, and fitted RRs at 0.2 Gy were 1.7, 1.9 and 3.3. For <5 years since exposure, there were three cases and the RR was not estimable. An important question was whether a similar latency applied for those exposed only at low doses. For <0.2 Gy, there were 3, 13 and 20 exposed cases for 5-9, 10-14 and 15-19 years since exposure, respectively, and fitted RRs at 0.2 Gy were 2.9 (95% CI, <0.0, 11.7), 6.2 (95% CI, 2.8, 13.5) and 5.5 (95% CI, 2.6, 10.6). For <0.1 Gy, there were 3, 10 and 8 exposed cases in the time since exposure categories and estimated RRs at 0.2 Gy were 3.5 (95% CI, 0.7, 11.1), 4.8 (95% CI, 1.8, 10.5) and 1.6 (95% CI, 0.3, 4.1). While data were limited, fitted RRs in the restricted data appeared compatible with a minimum latency of 5-10 years.

We previously identified an additive (non-synergistic) relationship for the RRs of thyroid radiation dose and chemotherapy for childhood cancer and thyroid cancer incidence (8). We refitted models for two subsets of the data to remove any residual uncertainty about a non-synergistic relationship chemotherapy: (i) participants who did not receive chemotherapy; and (ii) participants in the seven non-CCSS studies. The estimated ERR/Gy was 11.0 for participants without chemotherapy and 11.1 for the seven cohorts, resulting in fitted RRs at 0.2 Gy of 3.2 for both
subsets. This equaled the fitted RR of 3.2 for data with doses <0.2 Gy, indicating choice of risk model for chemotherapy did not impact results.

Vaccarella et al have suggested that increased medical surveillance and new diagnostic techniques are important factors in recent worldwide increases in the incidence rates for thyroid cancer (30). While medical screening may have increased the ascertainment of thyroid cancer cases, there was little reason to presuppose that increased screening was also related to radiation dose and thus acted to confound our results. Information on thyroid cancer screening practices was not explicitly available for all studies in our pooling; however, analytic evaluation was possible in two studies. Ron et al. considered the effect of screening using surrogate information on the potential for heightened medical surveillance in the Atomic Bomb Survivors Study and the Michael Reese Hospital Study (10). For the former, Ron et al evaluated participation in the Adult Health Study, a companion study starting in 1958 that involved approximately 20% of subjects who were invited to biennial clinical examinations. For the latter, Ron et al used calendar year 1974 as an approximate indicator year for the start of heightened public awareness of radiation effects and heightened surveillance. Analyses revealed the expected increase in the absolute rate of thyroid cancer incidence, but also found no significant variation in the radiation dose-response for the RR of thyroid cancer (10). In the current analysis of restricted data, we similarly found no significant variation in the linear radiation dose-response parameter by participation in the Adult Health Study for the Atomic Bomb Survivor Study (P=0.39). With one case, we could not assess the Michael Reese Hospital Study. We also evaluated variation of the radiation dose-response across categories of calendar year of follow-up, reasoning that confounding from enhanced thyroid screening was more likely to have occurred in recent years. After adjustment for attained age, we found no significant variation of the radiation dose-response by calendar year (P=0.32).

With the nuclear releases from the 1986 Chernobyl power plant accident and from the Fukushima Daiichi power plant following the 2011 Great East Japan Earthquake and Tsunami, there are questions about comparative thyroid cancer risks for childhood exposure to low radiation doses from external and internal sources. External sources of exposure derive mainly from x and γ-irradiation, while internal sources derive mainly from short-lived β-radiation decay of iodine-131 (1, 31-35). Studies of thyroid cancer in children exposed following the Chernobyl accident have reported a range of RR s. RR estimates at 0.2 Gy were 1.9 from a Russian Federation-Belarus study (36), 1.9 from a Ukraine study (37), with a more recent estimate of 1.2 (38), and 1.2 from a Belarus study (39). Our analysis of external thyroid radiation dose yielded an estimate of 3.2 (95% CI, 2.3, 4.3). For those aged <5 years at exposure, RR estimates at 0.2 Gy were 2.6 in the Ukraine study (37) and 1.9 in the Belarus study (39), while our estimate was 3.4 (95% CI, 2.0, 4.8). These results suggested the possibility of a slightly greater thyroid cancer risk from childhood external irradiation. Definitive conclusions are problematic due to the substantial differences between our populations of medically exposed individuals and atomic bomb survivors and the Chernobyl-exposed populations who were mildly to moderately iodine deficient and/or intensely screened (40).

The use of computed tomography (CT) scanning for medical diagnostic and therapeutic procedures has increased substantially in recent years in both adults and children, with children in the U.S. now receiving 5 to 9 million scans per year (41, 42) (http://www.cancer.gov/about-cancer/causes-prevention/risk/radiation/pediatric-ct-scans). CT scans of children can result in thyroid radiation doses of 0.010 Gy for head CTs (38, 43), 0.027 Gy for chest CTs (43-45), 0.050 Gy for neck CTs (46, 47), 0.036 Gy for cervical spine CTs (48) and 0.008 Gy for abdominal CTs (43). With CT scans often repeated, multi-detector row CT scans reducing scan times and enabling increased use of CT scans in pediatric medicine and the use of multi-phase (repeat
scanning before and after contrast injection) CT examinations, there is a high potential for pediatric patients to receive thyroid doses for which there is a demonstrably increased risk of thyroid cancer.

For a given total dose, the number of radiation treatments did not modify risks, although numbers of thyroid cancer cases with multiple treatments were limited (the Israel Tinea study, Hemangioma-Stockholm study and Hemangioma-Göteborg study contributed 10, 9 and 1 cases, respectively). Pooled analyses of seven studies, a subset of the current studies (10), 12 studies across the full range of doses including 144 cases with multiple treatments (8), and our current analysis do not support a significant dose fractionation effect. Notably, these analyses did observe a reduced strength of association with multiple radiation treatments, albeit not statistically significant. Harmonization of fractionation data was challenging due to diverse and calendar year varying treatment protocols and limited information on treatment specifics for the studies. Various definitions of dose fraction were possible. Due to harmonization necessities, we defined one treatment as all radiation doses received within six months. This resulted in the large majority of patients receiving one radiation “treatment”, diminishing our ability to evaluate fractionation.

In conclusion, these analyses reinforced the existence of an excess thyroid cancer risk at doses <0.2 Gy and <0.1 Gy, and perhaps at even lower doses. The consistency of the linear radiation dose-response at low doses and the apparent absence of a significant radiation fractionation effect reaffirm that the direct application of a linear relationship remains the most plausible approach for the extrapolation of radiation-associated thyroid cancer risk (49) and adds support to the use of a linear model for ALARA assessments (50).

Acknowledgements
We would also like to acknowledge members of the Nordic Countries Childhood Cancer Survivor Study Group, who have contributed to the Nordic Countries Childhood Cancer Survivor Study, including: H. Hertz, J. Olsen (Denmark); G. Jonmundsson, H. Tulinius (Iceland); M. Lanning, R. Sankila (Finland); and H. Døllner, F. Langmark (Norway). We also wish to recognize the late Dr. Elaine Ron, who initiated and guided this pooling project.

Corresponding author and person to whom reprint requests should be addressed: Jay H. Lubin, Ph.D. Division of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, National Institutes of Health, Tel: 240.276.7426, Fax: 240.276.7838, Email: lubinj@mail.nih.gov

Funding support: This study was supported by the Intramural Research Program of the U.S. National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics. The Childhood Cancer Survivor Study was funded by the National Cancer Institute grant U24 CA55727, the Lance Armstrong Foundation grant 147149 and the Intramural Research Program of the NIH, National Cancer Institute, Division of Cancer Epidemiology and Genetics. The enlarged thymus cohort was supported by NHLBI grant K-23 HL070930.

Disclosure statement: The authors have nothing to declare.
References


one standard deviation (thin grey line), the fitted linear excess relative risk model (solid black line) and a restricted cubic spline (dash-dot-dot line). Data pooled from nine cohort studies and limited to <0.2 Gy (main panel) or <0.1 Gy (inset). Also, the linear-exponential-linear model (Appendix equation 3) fitted to all data with the full range of doses (dash line).

Figure 2: Deviances for linear excess relative risk models given a threshold dose (η) (open symbol) (see text for model), with deviances rescaled to zero at the minimum deviance (star symbol), and a moving average smoothing. Dash line identifies one-sided 95% confidence limit. Data pooled from nine cohort studies and limited to <0.2 Gy (main panel) and <0.1 Gy (inset).

Figure 3: Fitted RRs at 0.2 and 0.1 Gy and 95% CIs under a linear excess relative risk model with effect modification by the natural logarithm of age at exposure divided by 5 years overall and sequentially omitting one study at a time. RRs reflect age five years at exposure. Dash line represents lower and upper confidence limits for all data.

Table 1: Numbers of thyroid cancer cases, participants, person-years (P-yrs) of follow-up, relative risks (RR), 95% confidence intervals (CI) and estimated radiation-associated excess cases. Pooled data for doses <0.2 Gy.

<table>
<thead>
<tr>
<th>Dose (gray)</th>
<th>Range</th>
<th>Mean</th>
<th>Cases</th>
<th>Participants</th>
<th>P-yrs</th>
<th>RR ⁴</th>
<th>95% CI</th>
<th>Excess ⁵</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>0.000</td>
<td>142</td>
<td>46,439</td>
<td>1,865,957</td>
<td>1.00</td>
<td></td>
<td>0.0</td>
</tr>
<tr>
<td></td>
<td>0.001-0.004</td>
<td>0.002</td>
<td>24</td>
<td>9,464</td>
<td>367,606</td>
<td>1.07</td>
<td>(0.7, 1.8)</td>
<td>0.4</td>
</tr>
<tr>
<td></td>
<td>0.005-0.02</td>
<td>0.009</td>
<td>30</td>
<td>13,796</td>
<td>587,614</td>
<td>1.21</td>
<td>(0.8, 1.9)</td>
<td>2.7</td>
</tr>
<tr>
<td></td>
<td>0.02-0.03</td>
<td>0.025</td>
<td>13</td>
<td>8,055</td>
<td>345,748</td>
<td>0.87</td>
<td>(0.5, 1.6)</td>
<td>4.6</td>
</tr>
<tr>
<td></td>
<td>0.04-0.06</td>
<td>0.049</td>
<td>54</td>
<td>7,204</td>
<td>315,014</td>
<td>2.01</td>
<td>(1.4, 2.8)</td>
<td>15.0</td>
</tr>
<tr>
<td></td>
<td>0.06-0.08</td>
<td>0.068</td>
<td>31</td>
<td>5,825</td>
<td>256,456</td>
<td>1.40</td>
<td>(0.9, 2.1)</td>
<td>16.9</td>
</tr>
<tr>
<td></td>
<td>0.08-0.09</td>
<td>0.088</td>
<td>32</td>
<td>5,335</td>
<td>242,247</td>
<td>1.78</td>
<td>(1.2, 2.7)</td>
<td>17.3</td>
</tr>
<tr>
<td></td>
<td>0.10-0.12</td>
<td>0.107</td>
<td>20</td>
<td>3,230</td>
<td>136,943</td>
<td>2.51</td>
<td>(1.5, 4.1)</td>
<td>9.4</td>
</tr>
<tr>
<td></td>
<td>0.12-0.14</td>
<td>0.126</td>
<td>21</td>
<td>3,537</td>
<td>149,525</td>
<td>2.63</td>
<td>(1.6, 4.2)</td>
<td>11.0</td>
</tr>
<tr>
<td></td>
<td>0.14-0.16</td>
<td>0.146</td>
<td>13</td>
<td>1,778</td>
<td>73,824</td>
<td>3.76</td>
<td>(2.1, 6.8)</td>
<td>5.5</td>
</tr>
<tr>
<td></td>
<td>0.16-0.19</td>
<td>0.172</td>
<td>14</td>
<td>2,741</td>
<td>113,582</td>
<td>2.41</td>
<td>(1.4, 4.3)</td>
<td>11.1</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td></td>
<td>394</td>
<td>107,594</td>
<td>4,454,516</td>
<td></td>
<td></td>
<td>93.8</td>
</tr>
</tbody>
</table>

⁴ Relative risks adjusted for study, sex, age, other study-specific factors and chemotherapy exposure.
⁵ Estimated excess number of thyroid cancer cases above fitted background of non-exposed participants.
Table 2: Evaluation of effect modification for the thyroid cancer radiation dose response, including numbers of radiation exposed cases and fitted relative risks (RR) at 0.2 Gy under an additive adjustment for treatment with chemotherapy. Pooled data limited to doses <0.2 Gy or <0.1 Gy.

<table>
<thead>
<tr>
<th>Modifier</th>
<th>Cases</th>
<th>RR&lt;sub&gt;0.2 Gy&lt;/sub&gt;</th>
<th>θ</th>
<th>Cases</th>
<th>RR&lt;sub&gt;0.2 Gy&lt;/sub&gt;</th>
<th>θ</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Data with doses &lt; 0.2 Gy</td>
<td>Data with doses &lt; 0.1 Gy</td>
<td>Data with doses &lt; 0.2 Gy</td>
<td>Data with doses &lt; 0.1 Gy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>252</td>
<td>3.2</td>
<td>2.84</td>
<td>184</td>
<td>2.9</td>
<td>2.17</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>58</td>
<td>4.2</td>
<td>2.93</td>
<td>44</td>
<td>5.0</td>
<td>2.31</td>
</tr>
<tr>
<td>Female</td>
<td>194</td>
<td>3.0</td>
<td>2.4</td>
<td>140</td>
<td>2.4</td>
<td></td>
</tr>
<tr>
<td>P-value&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.35</td>
<td>0.15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at exposure (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1</td>
<td>40</td>
<td>1.6</td>
<td>3.49</td>
<td>30</td>
<td>0.4</td>
<td>2.77</td>
</tr>
<tr>
<td>1-4</td>
<td>64</td>
<td>4.2</td>
<td>3.1</td>
<td>31</td>
<td>2.9</td>
<td></td>
</tr>
<tr>
<td>5-9</td>
<td>84</td>
<td>3.9</td>
<td>71</td>
<td>3.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10-14</td>
<td>42</td>
<td>3.5</td>
<td>35</td>
<td>3.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15-19</td>
<td>22</td>
<td>1.6</td>
<td>17</td>
<td>0.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-value&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.01</td>
<td>0.05</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Attained age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;20</td>
<td>17</td>
<td>9.4</td>
<td>3.72</td>
<td>10</td>
<td>7.5</td>
<td>2.49</td>
</tr>
<tr>
<td>20-29</td>
<td>43</td>
<td>5.5</td>
<td>25</td>
<td>4.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30-39</td>
<td>48</td>
<td>2.6</td>
<td>33</td>
<td>2.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40-49</td>
<td>60</td>
<td>2.2</td>
<td>48</td>
<td>2.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>50-59</td>
<td>62</td>
<td>3.1</td>
<td>52</td>
<td>3.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>60+</td>
<td>22</td>
<td>2.5</td>
<td>16</td>
<td>1.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-value&lt;sup&gt;d&lt;/sup&gt;</td>
<td>0.01</td>
<td>0.13</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time since exposure (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;20</td>
<td>37</td>
<td>5.3</td>
<td>3.16</td>
<td>22</td>
<td>4.2</td>
<td>2.41</td>
</tr>
<tr>
<td>20-29</td>
<td>49</td>
<td>3.5</td>
<td>36</td>
<td>3.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30-34</td>
<td>33</td>
<td>3.4</td>
<td>22</td>
<td>1.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>35-39</td>
<td>33</td>
<td>3.3</td>
<td>22</td>
<td>2.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40-44</td>
<td>36</td>
<td>2.4</td>
<td>28</td>
<td>2.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>45+</td>
<td>64</td>
<td>2.3</td>
<td>54</td>
<td>3.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-value&lt;sup&gt;d&lt;/sup&gt;</td>
<td>0.02</td>
<td>0.26</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of treatments&lt;sup&gt;e&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>226</td>
<td>3.5</td>
<td>2.80</td>
<td>170</td>
<td>3.4</td>
<td>2.13</td>
</tr>
<tr>
<td>≥2</td>
<td>20</td>
<td>2.4</td>
<td>8</td>
<td>0.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-value&lt;sup&gt;f&lt;/sup&gt;</td>
<td>0.25</td>
<td>0.25</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Fitted RRs from a linear model in radiation dose with an additive effect for chemotherapy treatment, c, RR (d, x<sub>j</sub>) = 1 + β<sub>d</sub> + θ<sub>c</sub>. Models adjusted for study, sex, age and study-specific factors (see text). For modifiers, \( \sum \beta_j, z_j, d \) replaced β<sub>d</sub> where z<sub>j</sub> was an indicator variable for category j and β was a linear parameter. There were 142 with non-exposed cases. For <0.2 Gy and <0.1 Gy, β estimates with 95% confidence interval were 11.1 (6.6, 19.7) and 9.6 (3.7, 17.0), respectively.

<sup>b</sup>Fitted RR at 0.2 Gy.

<sup>c</sup>P-value for likelihood ratio test of no variation based on a binary modifier.

<sup>d</sup>P-value for likelihood ratio test of no variation based on continuous modifier.

<sup>e</sup>The definition of fractionation, which involved time between fractions, dose per fraction and reason, varied by study. One treatment included all dose fractions received within six months in most studies and within one year for the Tinea Capitis study.